GNAS anticorps (N-Term)
Aperçu rapide pour GNAS anticorps (N-Term) (ABIN630225)
Antigène
Voir toutes GNAS AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- N-Term
-
Specificité
- GNAS antibody was raised against the N terminal of GNAS
-
Purification
- Purified
-
Immunogène
- GNAS antibody was raised using the N terminal of GNAS corresponding to a region with amino acids SGKSTIVKQMRILHVNGFNGDSEKATKVQDIKNNLKEAIETIVAAMSNLV
-
-
-
-
Indications d'application
-
WB: 2.5 µg/mL, IHC: 4-8 µg/mL
Optimal conditions should be determined by the investigator. -
Commentaires
-
GNAS Blocking Peptide, (ABIN5613808), is also available for use as a blocking control in assays to test for specificity of this GNAS antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of GNAS antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- GNAS (GNAS Complex Locus (GNAS))
-
Autre désignation
- GNAS
-
Sujet
- Mutations in GNAS gene result in pseudohypoparathyroidism type 1a, pseudohypoparathyroidism type 1b, Albright hereditary osteodystrophy, pseudopseudohypoparathyroidism, McCune-Albright syndrome, progressive osseus heteroplasia, polyostotic fibrous dysplasia of bone, and some pituitary tumors.
-
Poids moléculaire
- 42 kDa (MW of target protein)
-
Pathways
- Thyroid Hormone Synthesis, cAMP Metabolic Process, Myometrial Relaxation and Contraction, Embryonic Body Morphogenesis
Antigène
-